360° SearchNetwork Hot Spots Trends Time Series

Polymerase

Type: Keyphrase

Name: Polymerase

First reported May 17 2013 - Updated May 17 2013 - 1 reports

AstraZeneca moves 3 cancer compounds to Phase III development

AstraZeneca has enrolled its first patient into a Phase II clinical trial for moxetumomab pasudotox, which is a treatment for unresponsive or relapsed hairy cell leukaemia patients.Three of its cancer compounds are being moved forward to Phase III clinical ... [Published Labmate Online - May 17 2013]

Entities: AstraZeneca PLC, Phase III, Cancer, Olaparib

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Kinetic Characterization of Exonuclease-Deficient Staphylococcus aureus PolC, a C-family Replicative DNA Polymerase

by Indrajit Lahiri, Purba Mukherjee, Janice D. PataPolC is the C-family replicative polymerase in low G+C content Gram-positive bacteria. To date several structures of C-family polymerases have been reported, including a high resolution crystal structure ... [Published Elites TV - May 17 2013]

Entities: Polymerase, Staphylococcus Aureus, DNA Polymerase

First reported May 16 2013 - Updated May 16 2013 - 1 reports

AstraZeneca PLC

AZ puts three targeted cancer drugs into Phase III

Having recently stressed that oncology is a core therapy area for its research, AstraZeneca is moving three of its cancer compounds into Phase III trials.First up, MedImmune, AstraZeneca’s biologics R&D arm, has enrolled the first patient in a late-stage ... [Published Pharma Times - May 16 2013]

Entities: Phase III, Cancer, AstraZeneca PLC, Olaparib

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Scien.net Publishes New Polymerase & Reductase Bibliography

The novel Natural Sciences Bibliographic Web Portal aims to provide comprehensive bibliographic information on the basic and applied life, earth and health sciences and has published over 184,800 references and 133,600 tags. Scien.net has now newly included ... [Published PRWeb - May 16 2013]

Entities: Polymerase, Enzyme, Ribonucleic Acid

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Enhancing in vitro selection techniques to assist the discovery, understanding and use of inorganic binding peptides

Reflecting the increasing interest in combinatorial approaches, Peptide Phage display has seen an unprecedented expansion in a wide range of research areas. Its application to the discovery and analysis of metal binding peptides has opened up new research ... [Published RSC - May 15 2013]

Entities: Peptide, Inorganic, In Vitro

First reported May 13 2013 - Updated May 13 2013 - 1 reports

Quantification of Cellular Poly(ADP-ribosyl)ation by Stable Isotope Dilution Mass Spectrometry Reveals Tissue- and Drug-Dependent Stress Response Dynamics

Poly(ADP-ribosyl)ation is an essential post-translational modification with the biopolymer poly(ADP-ribose) (PAR). The reaction is catalyzed by poly(ADP-ribose) polymerases (PARPs) and plays key roles in cellular physiology and stress response. PARP inhibitors ... [Published ACS Chemical Biology - May 13 2013]

Entities: Lymphocyte, DILUTION, Stable Isotope

First reported May 09 2013 - Updated May 09 2013 - 1 reports

Structures of Coxsackievirus, Rhinovirus, and Poliovirus Polymerase Elongation Complexes Solved by Engineering RNA Mediated Crystal Contacts

by Peng Gong, Matthew G. Kortus, Jay C. Nix, Ralph E. Davis, Olve B. PeersenRNA-dependent RNA polymerases play a vital role in the growth of RNA viruses where they are responsible for genome replication, but do so with rather low fidelity that allows ... [Published Elites TV - May 09 2013]

Entities: RNA, Polymerase, Elongation, Poliovirus, Rhinovirus

First reported May 09 2013 - Updated May 09 2013 - 1 reports

Bacterial DNA polymerases participate in oligonucleotide recombination

Synthetic single‐strand oligonucleotides (oligos) with homology to genomic DNA have proved to be highly effective for constructing designed mutations in targeted genomes, a process referred to as recombineering. The cellular functions important for this ... [Published Bionity.com - May 09 2013]

Entities: Recombination, Oligo, DNA, Bacterial, Polymerase

First reported May 07 2013 - Updated May 07 2013 - 2 reports

All-oral Hep C race heats up as Abbvie receives "breakthrough" status

AbbVie joined BMS today in gaining Breakthrough Therapy designation for an investigational Hep C treatment. The three drug combo of ABT-450/r (protease inhibitor and ritonavir), ABT-267 (an NS5A inhibitor) and ABT-333 (a non-nucleoside polymerase inhibitor) ... [Published Medical Marketing And Media - May 07 2013]

Entities: AbbVie, Phase II, ritonavir, John Leonard

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Discovery of the First C-Nucleoside HCV Polymerase Inhibitor (GS-6620) with Demonstrated Antiviral Response in HCV Infected Patients

Gilead Sciences, 333 Lakeside Drive, Foster City, California 94044, United States ... [Published Journal of Medicinal Chemistry - May 01 2013]

Entities: Polymerase, Antiviral, Patient, Foster City (United States), Gilead Sciences Inc

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

In Vitro Resistance to ALS-2200, a Potent Nucleotide Polymerase Inhibitor for the Treatment of Chronic Hepatitis

Reported by Jules LevinEASL 2013 April 28 Amsterdam EASL: - (04/27/13) median 4 to 4.5 log HCV RNA reductions were seen in this study presented in a poster at EASL. EASL: - (04/23/13) C Tan, H., Jekle, A., Kang, H., Moy, C., Deval, J., *Tigges, A., *Zhang, ... [Published National AIDS Treatment Advocacy Project - Apr 30 2013]

Entities: Polymerase, Nucleotide, In Vitro, Hepatitis

First reported Apr 27 2013 - Updated Apr 27 2013 - 2 reports

3 Healthcare Stock Stories for Weekend Wellness

Avanir Pharmaceuticals ( NASDAQ: AVNR ): Closing price $3.29Avanir announced Friday that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for Nuedexta (dextromethorphan hydrobromide and ... [Published Wall St. Cheat Sheet - Apr 27 2013]

Entities: CareFusion Corp, Health Care, Quinidine Sulfate, NUEDEXTA

Quotes

...of this regimen to be important in the treatment of HCV," said John M Leonard, M D , senior vice president and chief scientific officer, AbbVie. "Our HCV program is one part of our advancing pipeline which is focused on delivering innovative therapies to address pressing areas of unmet clinical need."

AbbVie receives breakthrough therapy designation from FDA for HCV regimen [Published Zecco - May 17 2013]

"Conclusions: If the past is a harbinger of the future, therapy for HCV infection will probably continue to advance at a brisk pace. Many additional potent agents are in the clinical pipeline, and interferon-free regimens are likely to dominate the HCV therapeutic landscape within the next 5 years. If a simple treatment regimen becomes a reality, a robust health care infrastructure will be needed to identify, triage, and treat the millions of HCV-infected patients who are unaware of their status. The infrastructure in the current U S health care system is woefully inadequate. The rate of death from HCV infection has already outpaced the rate of death from HIV infection in the United States.71 Successful treatment of HCV infection has undeniable long-term benefits with respect to reducing morbidity and mortality.26-29Perhaps the most challenging issue is not whether there will be medical tools to effectively manage and treat HCV infection, but rather whether the economic resources and societal commitment will be adequate to embark on an ambitious agenda to eliminate this global public healthhealth problem."

Current and Future Therapies for Hepatitis C Virus Infection, from NIH [Published National AIDS Treatment Advocacy Project - May 17 2013]

...Mary Lynne Hedley, President of TESARO. "We remain on track to begin enrolling patients in a Phase 3 trial in the ovarian cancer maintenance setting by mid-year, and to initiate a Phase 3 trial in patients with breast cancer during the second half of 2013."

Vascular Files Patent Infringement Complaint Against Boston Scientific; Tesaro Demonstrate Activi ... [Published BioMedReports - May 17 2013]

...Pangalos, head of innovative medicines and early development at AstraZeneca, said that cancer is "one of our three core therapy areas", and the "progress we are making with olaparib and selumetinib, combined with our broader early phase portfolio across small molecules and biologics, puts us in a strong position to deliver our pipeline of targeted cancer medicines"

AZ puts three targeted cancer drugs into Phase III [Published Pharma Times - May 16 2013]

More Content

sort by: Date \| Relevance
Identification of the Causative Gene for Simmen... [Published Elites TV - May 17 2013]
AstraZeneca moves 3 cancer compounds to Phase I... [Published Labmate Online - May 17 2013]
AbbVie receives breakthrough therapy designatio... [Published Zecco - May 17 2013]
Kinetic Characterization of Exonuclease-Deficie... [Published Elites TV - May 17 2013]
Current and Future Therapies for Hepatitis C Vi... [Published National AIDS Treatment Advocacy Project - May 17 2013]
Vascular Files Patent Infringement Complaint Ag... [Published BioMedReports - May 17 2013]
AZ puts three targeted cancer drugs into Phase III [Published Pharma Times - May 16 2013]
Chimerix's CMX001 Resistance Data Presented at ... [Published Yahoo! Finance - May 16 2013]
TESARO Announces Presentation of Niraparib Clin... [Published Yahoo! Finance - May 16 2013]
TESARO Announces Presentation of Niraparib Clin... [Published Morningstar.com - May 16 2013]
Chimerix's CMX001 Resistance Data Presented at ... [Published Morningstar.com - May 16 2013]
AstraZeneca issues update on accelerated oncolo... [Published European Pharmaceutical Review - May 16 2013]
Scien.net Publishes New Polymerase & Reductase ... [Published PRWeb - May 16 2013]
Inside Story Behind Glybera's Development and A... [Published Genetic Engineering News - May 16 2013]
Idenix Pharmaceuticals' CEO Presents at Bank of... [Published Seeking Alpha - May 16 2013]
ABBVIE INC: AbbVie to Present Data on Investiga... [Published 4 Traders - May 15 2013]
AbbVie to Present Data on Investigational Anti-... [Published ADVFN UK - May 15 2013]
"Methods and Compositions for Treating Hepatiti... [Published Equities.com - May 15 2013]
Enhancing in vitro selection techniques to assi... [Published RSC - May 15 2013]
New drug enhances radiation treatment for brain... [Published EurekAlert! - May 14 2013]
Ribonucleolytic resection of DNA breaks [Bioche... [Published PNAS - May 14 2013]
EASL 2013: Direct-acting Antivirals Boost Respo... [Published HIV and Hepatitis.com - May 14 2013]
AbbVie's Investigational HCV Regimen Receives B... [Published National AIDS Treatment Advocacy Project - May 14 2013]
Method for pairwise sequencing of target polynu... [Published PharmCast - May 14 2013]
H7N9: From anxiety to preparedness [Published H5N1 - May 13 2013]
Quantification of Cellular Poly(ADP-ribosyl)ati... [Published ACS Chemical Biology - May 13 2013]
U.S. FDA grants priority review to Simeprevir f... [Published Presscontacts.com - May 13 2013]
Medivir: U.S. FDA grants priority review to Sim... [Published Zecco - May 13 2013]
Part 1: Will Array BioPharma Become A Late-Stag... [Published Seeking Alpha - May 12 2013]
New method for the early detection of vineyard ... [Published Web Newswire - May 12 2013]

Blogs

sort by: Date \| Relevance
H7N9: From anxiety to preparedness [Published H5N1 - May 13 2013] Many thanks to Greg Folkers for sending the link to this just-published opinion piece in Annals of Internal Medicine: Influenza A(H7N9): From Anxiety to Preparedness. It deals with two questions: Should we be concerned? And are we fully prepared for a ...
Single gene swap helps H5N1 switch hosts [Published H5N1 - May 02 2013] Via ScienceNow, a report by Martin Enserink discussing work done by Chen Hualan of Harbin Veterinary Research Institute in China: Single Gene Swap Helps Bird Flu Virus Switch Hosts. Click through for the full report and many links. Excerpt:Instead of ...
The origin, evolution, and functional impact of... [Published Genome Research current issue - May 01 2013] Short insertions and deletions (indels) are the second most abundant form of human genetic variation, but our understanding of their origins and functional effects lags behind that of other types of variants. Using population-scale sequencing, we have ...
Combination Drugs are the Future of the Europea... [Published Pharma-Mag - Apr 30 2013] Benefits include improved drug efficiency, reduced pill burden, and lower dosage frequency. The limited efficacy and negative side-effects associated with current therapeutics for Hepatitis B and C are highlighting the urgent need for new, improved ...
3 Healthcare Stock Stories for Weekend Wellness [Published Wall St. Cheat Sheet - Apr 27 2013] Avanir Pharmaceuticals ( NASDAQ: AVNR ): Closing price $3.29Avanir announced Friday that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for Nuedexta (dextromethorphan hydrobromide and ...

Press Releases

sort by: Date \| Relevance
Transgene Presents Promising Pre-Clinical Data ... [Published Business Wire - Apr 29 2013]
Ligand Presents Preclinical Data on HepDirect™ ... [Published Business Wire Health News - Apr 26 2013]
SCYNEXIS Presents SCY-635 Data on HCV at Intern... [Published Business Wire - Apr 25 2013]
Annual Report 2012 [Published GlobeNewswire: Acquisitions News - Apr 04 2013]
Medivir: Annual Report 2012 [Published Business Wire Health News - Apr 04 2013]